INAF - PT. Indofarma Tbk

Rp 2.430

-80 (-3,29%)

JAKARTA – PT Indofarma (Persero) Tbk (INAF) records the sales of IDR 849.32 billion. It soars extensively by 90% from IDR 402.02 billion in the same period in 2020, supported by the sales in the health devices and medications segments. Corporate Secretary of Indofarma, Warjoko Sumedi, reveals the gain through the press release, quoted Monday (2/8).

“The company is consistently trying to utilise opportunities to create a sustainable business amidst this condition and continue to contribute to the community,” Sumedi adds.

The strategies to solidify INAF’s performance include turnaround management, product portfolio strategy, and supply chain management.

It is further mentioned that Indofarma manages to secure IDR 187 billion in its EBITDA. It exponentially escalates by 685% from IDR 24 billion reported in the same period last year. Furthermore, its assets increase 7% from IDR 1.82 trillion to IDR 1.95 trillion, while its liability also climbs 9% from IDR 1.38 trillion to IDR 1.52 trillion.

Regarding the COVID-19 response, Indofarma has manufactured essential drugs for treating the virus, including Oseltamivir Phosphate 75 mg, Ivermectin 12 mg, Ivercov 12, Desrem, and Zinkid. It also conducts vaccinations and provides health equipment to treat the COVID-19 pandemic. (LK/ZH)